1.33
Pepgen Inc Aktie (PEPG) Neueste Nachrichten
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc.PEPG - Bluefield Daily Telegraph
Is PepGen (NASDAQ:PEPG) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
PepGen Inc.’s CEO Makes Bold Stock Purchase! - TipRanks
PepGen president and CEO McArthur buys shares worth $47,724 By Investing.com - Investing.com Canada
PepGen president and CEO McArthur buys shares worth $47,724 - Investing.com
PepGen Inc. (PEPG) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
PepGen stock plunges to 52-week low of $1.14 amid market challenges - Investing.com Canada
PepGen stock plunges to 52-week low of $1.14 amid market challenges By Investing.com - Investing.com South Africa
PepGen (NASDAQ:PEPG) Stock Price Down 14.4% – Time to Sell? - Defense World
PepGen to Present at the 24th Annual Needham Virtual Healthcare Conference - BioSpace
PepGen Announces Appointment of Two New Directors to its Board - BioSpace
PepGen Appoints Lisa Wyman and Mitchell Finer to its Board of Directors - citybiz
PepGen Inc. Expands Board with New Appointments - TipRanks
PepGen names two new directors to board - TipRanks
PepGen CMO Mellion resigns, effective April 4 - Investing.com Australia
PepGen CMO Mellion resigns, effective April 4 By Investing.com - Investing.com South Africa
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen IncPEPG - Bluefield Daily Telegraph
PEPG ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of PepGen Inc. Shareholders Who Lost Money - ACCESS Newswire
PepGen Announces Presentations at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference - Business Wire
PepGen Inc. Investigated by Shareholder Rights AdvocatesInvestors Should Contact Levi & Korsinsky Regarding Potential Securities Law ViolationsPEPG - ACCESS Newswire
PepGen Inc. Faces Clinical Trial Challenges and Competitive Pressures Leading to Sell Rating - TipRanks
What Do Analysts Think Will Happen To PepGen Inc (NASDAQ: PEPG) - Stocks Register
PepGen pauses Phase II DMD trial to review safety data - Yahoo Finance
PepGen To Voluntarily Pause Mid-Stage Duchenne Muscular Dystrophy Study, Stock Falls - Benzinga
PepGen Announces Update to Phase 2 CONNECT2-EDO51 Study in Patients with DMD - Marketscreener.com
Boston biotech's stock drops after Duchenne trial pause - The Business Journals
PepGen to pause CONNECT2-EDO51 study - TipRanks
PepGen slumps after pausing mid-stage study of Duchenne drug - TradingView
PepGen pauses phase 2 DMD study to review earlier trial data - Investing.com India
Pepgen Announces Update To Phase 2 Connect2-Edo51 Study In Patients With DMD -March 04, 2025 at 08:18 am EST - Marketscreener.com
PepGen stock slides after trial pause (PEPG:NASDAQ) - Seeking Alpha
Pepgen Announces Update To Phase 2 Connect2-Edo51 Study In Patients With DMD - TradingView
PepGen to Participate in Upcoming Investor Conferences - Business Wire
AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week - Asianet Newsable
PepGen Sees Fastest Weekly Retail Following Growth Among Biotech Stocks: What's Behind The Buzz? - Asianet Newsable
PepGen (PEPG) to Release Quarterly Earnings on Wednesday - Defense World
PEPG Stock Price and Chart — NASDAQ:PEPG - TradingView
Q1 Earnings Estimate for PepGen Issued By HC Wainwright - MarketBeat
Q1 Earnings Forecast for PepGen Issued By Leerink Partnrs - MarketBeat
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):